Rwanda & Gilead Sciences

Rwanda: Rwanda has been mentioned in the context of border restrictions with the Democratic Republic of the Congo to prevent the spread of Ebola, and its alleged backing of the March 23 Movement rebel group.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Rwanda: Rwanda>>> has closed its land border with the Democratic Republic of the Congo>>> as a precautionary measure against the spread of Ebola.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

Rwanda: Deployed specialists and supplies to support M23-controlled areas; accused of backing rebels.

Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.

Rwanda: Accused of backing M23; tensions affect regional stability and response.

Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.

Rwanda: Rwanda has been implicated in backing the March 23 Movement, which controls areas affected by the Ebola outbreak, and has closed its borders to the Democratic Republic of the Congo.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

Rwanda: Continued to record progress in reducing HIV infections despite funding constraints.

Gilead Sciences: Facing pressure to expand access to lenacapavir; its pricing and licensing decisions are under scrutiny.

Rwanda: Rwanda is mentioned as backing the March 23 Movement, which complicates the Ebola response in eastern Democratic Republic of the Congo.

Gilead Sciences: Gilead Sciences' antiviral remdesivir is mentioned as a potential treatment to be used at the quarantine facility, indicating its role in the medical response to Ebola.